Table 1 Association of HDAC7/USP10/c-Myc expression with clinicopathological parameters of patients with ESCC [n (%)]
Category | Total (n = 148) | HDAC7 expression | USP10 expression | c-Myc expression | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Low (n = 79) | High (n = 69) | P-value | Low (n = 72) | High (n = 76) | P-value | Low (n = 73) | High (n = 75) | P-value | ||
Age | 0.154 | 0.301 | 0.669 | |||||||
< 60 years | 45 (30.4) | 28 (35.4) | 17 (24.6) | 19 (26.4) | 26 (34.2) | 21 (28.8) | 24 (32.0) | |||
≥ 60 years | 103 (69.6) | 51 (64.6) | 52 (75.4) | 53 (73.6) | 50 (65.8) | 52 (71.2) | 51 (68.0) | |||
Gender | 0.982 | 0.156 | 0.734 | |||||||
Male | 120 (81.1) | 64 (81.0) | 56 (81.2) | 55 (76.4) | 65 (85.5) | 60 (82.2) | 60 (80.0) | |||
Female | 28 (18.9) | 15 (19.0) | 13 (18.8) | 17 (23.6) | 11 (14.5) | 13 (17.8) | 15 (20.0) | |||
Tumor location | 0.388 | 0.381 | 0.294 | |||||||
Upper | 8 (5.4) | 6 (7.6) | 2 (2.9) | 4 (5.6) | 4 (5.3) | 6 (8.2) | 2 (2.6) | |||
Middle | 76 (51.4) | 38 (48.1) | 38 (55.1) | 41 (56.9) | 35 (46.0) | 35 (48.0) | 41 (54.7) | |||
Lower | 64 (43.2) | 35 (44.3) | 29 (42.0) | 27 (37.5) | 37 (48.7) | 32 (43.8) | 32 (42.7) | |||
Tumor invasion | 0.075 | 0.177 | 0.811 | |||||||
T1–T2 | 13 (8.8) | 10 (12.7) | 3 (4.3) | 4 (5.6) | 9 (11.8) | 6 (8.2) | 7 (9.3) | |||
T3–T4 | 135 (91.2) | 69 (87.3) | 66 (95.7) | 68 (94.4) | 67 (88.2) | 67 (91.8) | 68 (90.7) | |||
Lymphatic metastasis | 0.080 | 0.001 | 0.002 | |||||||
N0 | 80 (54.1) | 48 (60.8) | 32 (46.4) | 49 (68.1) | 31 (40.8) | 49 (67.1) | 31 (41.3) | |||
N1–N3 | 68 (45.9) | 31 (39.2) | 37 (53.6) | 23 (31.9) | 45 (59.2) | 24 (32.9) | 44 (58.7) | |||
Differentiation | 0.944 | 0.905 | 0.500 | |||||||
Well and moderate | 129 (87.2) | 69 (87.3) | 60 (87.0) | 63 (87.5) | 66 (86.8) | 65 (89.0) | 64 (85.3) | |||
Poor | 19 (12.8) | 10 (12.7) | 9 (13.0) | 9 (12.5) | 10 (13.2) | 8 (11.0) | 11 (14.7) | |||
pTNM stage | 0.047 | 0.001 | 0.003 | |||||||
I–II | 73 (49.3) | 45 (57.0) | 28 (40.6) | 46 (63.9) | 27 (35.5) | 45 (61.6) | 28 (37.3) | |||
III | 75 (50.7) | 34 (43.0) | 41 (59.4) | 26 (36.1) | 49 (64.5) | 28 (38.4) | 47 (62.7) | |||